Halle/Saale, Germany, June 24, 2008 – Scil Proteins Production GmbH, a biopharmaceutical company offering contract process development and GMP biomanufacturing, today announced the closing of a protein production deal with Swiss pharmaceutical firm Roche.
Under the terms of the deal, Roche will transfer technology and know-how for the production of recombinant plasminogen activator (rPA) to Scil Proteins Production GmbH. rPA is the active ingredient of Rapilysin for the treatment of acute myocardial infarction which is marketed by Actavis. Financial terms of the technology transfer agreement are not disclosed.
For the manufacturing, Scil Proteins Production will use its new GMP site which was opened in April this year. The facility has a fermentation capacity of up to 1000 liters and will be inspected by EMEA next year as a prerequisite for the production of material marketed in Europe.
“The deal validates our expertise in the manufacturing of highly complex proteins for commercial purposes.” said Ulrike Fiedler, CEO of Scil Proteins. “After the tech-transfer we prepare for the production of the market supply.”
About Scil Proteins Production
Scil Proteins Production GmbH is the contract manufacturing organisation of Scil Proteins GmbH, a privately held company specialized in the research, development and production of complex recombinant proteins. Scil Proteins is active in two business areas: The contract biomanufacturing of recombinant proteins for clinical trials and market and the development of innovative biological compounds such as a novel class of antibody mimetics called Affilins™. For more information, please visit www.scilproteins.com.
Contact:
Dr Ole Fütterer
Scil Proteins GmbH Heinrich-Damerow-Str. 1 D-06120 Halle Germany Tel. +49 (0) 345 27 99 63 30 Fax. +49 (0) 345 27 99 63 32
info@scilproteins.com
